As a benchmark to measure the ability and level of professional and technical talents, the title is a ladder and a channel for professional and technical talents' career development, and assumes an important function to guide and motivate professional and technical talents. For high-end talents, especially many returnee innovation and entrepreneurial talents, the title is not only related to the declaration of various scientific research funds, but also an "endorsement" of their professional ability. Recently, Suzhou Daily published a report of "Pilot Field for Biomedical Title Review", let's take a look at the "stage" of biomedical talents' own title review.

　　At the end of last year, Suzhou Industrial Park took the lead in launching the pilot biomedical engineering title review in China. With the release of the first batch of the employed list, this pilot initiative has achieved a number of innovations: biomedical engineering has a place in the domestic professional title sequence for the first time, the "Jiangsu Province Biomedical Engineering Professional and Technical Qualification Conditions" has been implemented for the first time, the returnee leaders can directly "jump" to apply for senior titles, and the industry has hired the first evaluation chairman represented by entrepreneurs. In the first batch of the evaluation list, there are 16 people on the list, 12 of whom were awarded senior titles in biomedical engineering.

　　A major change: whether it is talent by the enterprise to say

　　In the past, the judges of the title evaluation often came from colleges and universities, and the evaluation criteria also put more emphasis on education, papers, the number of patents held and other indicators. However, in this round of biomedical engineering assessment in the park, the characteristics of "academy" are changed, and whether it is talent or not is often decided by enterprises.

　　As one of the chairman members of the Suzhou Biomedical Engineering Senior Professional Technical Qualification Review Committee, Yu Qiang, founder and CEO of CGeneTech (Suzhou, China) Co., Ltd. "This time, the title review introduced a percentage-based tool, including evaluation conditions such as papers and performance innovation results that meet the growth rules and technical characteristics of talents in the field of biopharmaceuticals, while including the evaluation of innovation research and development and other performance as criteria, focusing on the quality of research results." Yu Qiang said that he comes from the corporate world, and the evaluation will look at the applicants' academic qualifications, but focus more on judging their ability to apply their knowledge to real-world problems, which brings more flexible and practical judgment criteria. "For talents with high professional and technical level, the review will relatively dilute the requirement of the number of papers, highlighting the evaluation of professional and technical personnel job performance by the employer, forming a practical evaluation of talent orientation." Yu Qiang said.

　　Industrial development as the guide to assess the professional ability of talent, the introduction of the business community judges is a major innovation this time. According to Jiang Weidong, deputy director of Human Resources and Social Security Bureau of the park, the park has not only set up a biomedical title evaluation expert pool with seven people as director members, but also hired a 70-member team of judges. Most of these judges come from enterprises and industries in order to play the main role of enterprises in talent assessment as much as possible. "We assess the title requirements to the main unit, open the port to enterprises, through the enterprise gatekeeper, so that enterprises in the evaluation of the combination of use of talent to retain and use the talent." Jiang Weidong said.

　　In addition, the park also innovated the assessment method, pioneered the participation of industry associations in title assessment, and the biomedical industry promotion association specifically undertakes title assessment. At the end of last year, the comprehensive service center of biomedical industry in Suzhou Biomedical Industry Park was opened. Relying on this position, the Biomedical Industry Promotion Association moved the service port forward and opened a special window in the comprehensive service center, which was served by a dedicated person and effectively improved the review efficiency.

　　In fact, "by me" will not only gradually form the main evaluation system to the employer, will also bring a lot of "surprise". Yu Qiang told reporters that he was successfully evaluated some years ago as a senior title of chemical engineering, smoothly in the College of Pharmacy of Soochow University as an industrial professor. This "cross-border" status makes it easier for him to understand the direction of the school's research and the details of talent training. "If enterprises can select and evaluate a group of talents with senior titles from a practical point of view, and establish contact with universities or institutes through them, they may be able to find the 'interface' of industry-university-research docking more precisely." In his opinion, with these talent "bridges", schools and enterprises can jointly develop a training system suitable for industrial talents in the future, and jointly create the "strongest magnetic field" for attracting and gathering talents.

About CGeneTech

　　Founded in 2010 in Suzhou Industrial Park, CGeneTech (Suzhou, China) Co., Ltd. has a core team with decades of international experience in the full life cycle of pharmaceuticals, and is dedicated to the development and industrialization of small molecule innovative drugs for breakthrough therapeutics. With its integrated drug discovery technology platform and diversified business vision, the company has built a rich pipeline of Class 1 innovative drugs covering various disease areas such as hypoglycemia and anticancer. Among them, Shengliptin phosphate is expected to fill the gap of original DPP-4 inhibitors in China, while the first generic drug for the treatment of rare disease multiple sclerosis, Teriflunomide tablets, has also been approved for marketing. In the future, the company will focus on the unmet clinical needs in China and around the world to develop innovative drugs with high patient accessibility and better efficacy to benefit patients worldwide.